Cost-benefit analyses for transportation projects usually value impacts on safety and travel time through experiments in which consumers of mobility ('drivers') choose between routes which differ in safety and travel time. This approach has been criticized for failing to consider that private choices may not fully reflect citizens' preferences over public goods and means, a concept known as the consumer-citizen duality. Recent empirical evidence has established that individuals do indeed assign comparatively more value to safety in their role as citizens than in their role as drivers. Our study aims to provide explanations for this finding by presenting four stated choice experiments in which respondents were asked to make choices, both as citizens and as drivers, between routes that differed in travel time and safety. Subsequently, respondents were asked to provide reasons for their choices. We identify five cognitive and five normative explanations. The cognitive explanations suggest that individuals make diverging choices because their perceptions of accident risk differ between the two roles. Drivers will assign a relatively low value to mitigating accident risk because they believe that: (1) such risks are trivial on an individual level; (2) their personal risk is lower than the average risk; (3) their personal risk is controllable; (4) they would not be able to distinguish relative safety levels in real life; and (5) their choices for others are more risk-averse than choices for themselves and, unlike citizens, they are not explicitly evaluating risky choices for others. The normative explanations involve that individuals believe that the government should assign more value to safety compared to individual drivers because: (6) as citizen they are more prone to base their choices on social norms which prescribe risk-averse behaviour in this context; (7) governments have a duty of care concerning the safety of the transportation network; (8) drivers have a relatively high degree of responsibility to reduce their own travel times; (9) governments should account for drivers' tendencies to choose faster routes by building safer ones; and (10) governments should ensure the safety of the road network because this allows drivers to choose the fastest route without being concerned about the impact of their route choice on accident risk.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.aap.2018.08.027 | DOI Listing |
Hemasphere
January 2025
Department of Internal Medicine, Hematology and Oncology, and Institute of Medical Genetics and Genomics, University Hospital Brno and Medical Faculty Masaryk University Brno Czech Republic.
In chronic lymphocytic leukemia, the reliability of next-generation sequencing (NGS) to detect variants ≤10% allelic frequency (low-VAF) is debated. We tested the ability to detect 23 such variants in 41 different laboratories using their NGS method of choice. The sensitivity was 85.
View Article and Find Full Text PDFFront Oncol
January 2025
Department of Clinical Development, POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company, Indianapolis, IN, United States.
Introduction: SPLASH (NCT04647526) is a multicenter phase III trial evaluating the efficacy and safety of [Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). This study leveraged a lead-in phase to assess tissue dosimetry and evaluate preliminary safety and efficacy, prior to expansion into a randomized phase. Here we report those results.
View Article and Find Full Text PDFBMC Med
January 2025
Health Emergencies Programme, World Health Organization, Geneva, Switzerland.
Background: Tecovirimat, an antiviral treatment for smallpox, was approved as a treatment for mpox by the European Medicines Agency in January 2022. Approval was granted under "exceptional circumstances" based on effectiveness found in pre-clinical challenge studies in animals and safety studies in humans showing minimal side effects. As clinical efficacy studies are still ongoing, there is currently limited information with regard to the acceptability of tecovirimat to treat mpox.
View Article and Find Full Text PDFInj Prev
January 2025
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Background: Driving under the influence of alcohol and other drugs contributes significantly to road traffic crashes worldwide. This study explored trends of alcohol, methylamphetamine (MA), 3,4-methylenedioxy-N-methylamphetamine (MDMA) and Δ9-tetrahydrocannabinol (THC), in road crashes from 2010 to 2019 in Victoria, Australia.
Methods: We conducted a cross-sectional analysis using data from the Victorian Institute of Forensic Medicine and Victoria Police, examining proscribed drug detections in road crashes.
Thromb Haemost
January 2025
Centre de Ressources et Compétences des Maladies Hémorragiques Constitutionnelles, CHU Clermont-Ferrand, Estaing Hospital, Clermont-Ferrand, France.
Background: The Hemophilia Functional Ability Scoring Tool (Hemo-FAST), consisting of a patient-reported outcome (PRO) part and a clinician-reported outcome (ClinRO) part, was developed as a rapid and effective tool to assess functional mobility in clinical practice. This study (NCT04731701) aimed to validate the psychometric properties of Hemo-FAST for assessment of joint health in people with haemophilia (PwH).
Methods: PwH A or B aged ≥18 years completed questionnaires including the PRO part of Hemo-FAST and the short-form 36 health survey (SF-36) during one study visit.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!